Executive Change

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 ( March 21, 2022 )   CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)         One CVS Drive , Woonsocket , Rhode Island 02895 (Address of principal executive offices) (Zip Code)       Registrant's telephone number, including area code:                    ( 401 ) 765-1500 Former name or former address, if changed since last report:       N/A   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share CVS New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐                   Section 5 – Corporate Governance and Management   Item 5.02       Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On March 21, 2022, Jonathan C. Roberts, the current Executive Vice President and Chief Operating Officer of CVS Health Corporation (“CVS Health”), informed CVS Health that he intends to retire from CVS Health in June 2022. At this time, CVS Health does not intend to appoint a new Chief Operating Officer. Section 9 – Financial Statements and Exhibits   Item 9.01         Financial Statements and Exhibits.   (d)   Exhibits.       Exhibit No.   Description 104   Cover Page Interactive Data File (embedded within the Inline XBRL).                     SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.         CVS HEALTH CORPORATION         Date:  March 25, 2022 By: /s/ Colleen M. McIntosh     Colleen M. McIntosh Senior Vice President, Chief Governance Officer, Corporate Secretary and Assistant General Counsel